insights_auto
Why is CNSY down 10.11%?
Dive Deeperchevron_right
CNSY:NASDAQ
Cerenome, Inc.
$1.60
arrow_downward
-10.11%(-0.18) 1D
$1.59
arrow_downward
-0.62% (-0.0100)bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CNSY...
Open
$1.81
High
$1.86
Low
$1.54
Mkt. cap
12.14M
Avg. vol.
128.11K
Volume
234.62K
52-wk high
$4.16
52-wk low
$1.54
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
Open
$1.81
High
$1.86
Low
$1.54
Mkt. cap
12.14M
Avg. vol.
128.11K
Volume
234.62K
52-wk high
$4.16
52-wk low
$1.54
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
News stories
From web sources and news partners
TipRanks
·
22 hours ago
Cerenome Updates Investor Presentation on CNS Oncology Strategy
Investing.com India
·
1 day ago
Form 4 Cerenome, Inc For: 1 October
Profile
Cerenome, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Cerenome, Inc.